Haleon Pakistan Limited (PSX: HALEON)

Market Cap	53.06B
Revenue (ttm)	30.42B
Net Income (ttm)	1.02B
Shares Out	117.05M
EPS (ttm)	8.72
PE Ratio	51.99
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	426,610
Open	422.50
Previous Close	412.19
Day's Range	419.99 - 453.41
52-Week Range	125.00 - 454.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Haleon Pakistan

Haleon Pakistan Limited engages in the research and development, manufacture, marketing, and sale of consumer healthcare products primarily in Pakistan. The company offers products in the areas of pain relief under the Panadol brand; oral health under the Sensodyne and Parodontax brand names; respiratory health under the Panadol CF, Sancos, T-Day, Tandegyl, and Actified brands; nutrition and gastrointestinal health under the CaC-1000 PLUS, ENO, and QalSium-D brand names; and skin health under the Physiogel, Hydrozole, SunBlock 60, Lamisil, Acne...

• Industry: Pharmaceutical Preparations
• Founded: 2015
• Employees: 478
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HALEON

Financial Performance

In 2022, Haleon Pakistan's revenue was 27.51 billion, an increase of 13.84% compared to the previous year's 24.16 billion. Earnings were 325.41 million, a decrease of -84.75%.